Telmisartan in Mild to Moderate Hypertensive Patients
Primary Purpose
Hypertension
Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Low dose of telmisartan
High dose of telmisartan
Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension
Eligibility Criteria
Inclusion Criteria:
- Patients with blood pressure levels of 140/90 mm Hg or higher (confirmed on 2 consecutive visits), who were 18 years old and older, regardless of sex
Exclusion Criteria:
- Suspected or known diagnosis of arterial hypertension with a secondary cause
- Women who were not using an effective method of contraception, or who were pregnant, or breast-feeding
- Systolic blood pressure > 200 mm Hg or diastolic blood pressure > 115 mm Hg
- Laboratory test values two fold above the upper normal limit
- Previous intolerance to angiotensin conversion enzyme inhibitors or angiotensin II blocker (AIIAR)
- New York Heart Association class III or IV heart failure
- History of stroke in the 6 months prior to entry into the study
- Uncontrolled type 2 diabetes mellitus, defined as fasting glucose levels > 140 mg/dL on 3 consecutive assessments
- Patients who were included in another investigational drug study in the past 30 days
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Low dose of telmisartan
High dose of telmisartan
Arm Description
4 week placebo run-in phase followed by 6 weeks of treatment with low dose of telmisartan
After 6 weeks of treatment with low dose of telmisartan, titration to high dose of telmisartan if blood pressure level is higher than 140/90 mm Hg
Outcomes
Primary Outcome Measures
Changes in systolic blood pressure (SBP) and diastolic blood pressure (DBP)
Blood pressure values were obtained 24 hours after the last dose (through values) at the office
Secondary Outcome Measures
Assessment of treatment response for SBP/DBP (in %)
Response categories:
SBP < 140 mm Hg or
DBP < 90 mm Hg or
BP reduction ≥ 10 mm Hg
Changes from baseline in blood pressure values
Analysis performed for the ambulatory blood pressure monitoring (ABPM) - subgroup
Number of patients with adverse events
Number of patients with clinically significant changes in laboratory values
Number of patients with clinically significant changes in ECG
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02260089
Brief Title
Telmisartan in Mild to Moderate Hypertensive Patients
Official Title
A Multicenter Open-label Study of the Efficacy and Safety of Telmisartan in Mild to Moderate Hypertensive Patients
Study Type
Interventional
2. Study Status
Record Verification Date
October 2014
Overall Recruitment Status
Completed
Study Start Date
March 2000 (undefined)
Primary Completion Date
July 2002 (Actual)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Boehringer Ingelheim
4. Oversight
5. Study Description
Brief Summary
To evaluate the efficacy and tolerability of telmisartan, given once a day to patients with mild to moderate hypertension, as well as to assess the 24-hour blood pressure profile with ABPM
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
134 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Low dose of telmisartan
Arm Type
Experimental
Arm Description
4 week placebo run-in phase followed by 6 weeks of treatment with low dose of telmisartan
Arm Title
High dose of telmisartan
Arm Type
Experimental
Arm Description
After 6 weeks of treatment with low dose of telmisartan, titration to high dose of telmisartan if blood pressure level is higher than 140/90 mm Hg
Intervention Type
Drug
Intervention Name(s)
Low dose of telmisartan
Intervention Type
Drug
Intervention Name(s)
High dose of telmisartan
Intervention Type
Drug
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
Changes in systolic blood pressure (SBP) and diastolic blood pressure (DBP)
Description
Blood pressure values were obtained 24 hours after the last dose (through values) at the office
Time Frame
Baseline, up to 12 weeks after start of treatment
Secondary Outcome Measure Information:
Title
Assessment of treatment response for SBP/DBP (in %)
Description
Response categories:
SBP < 140 mm Hg or
DBP < 90 mm Hg or
BP reduction ≥ 10 mm Hg
Time Frame
Baseline, up to 12 weeks after start of treatment
Title
Changes from baseline in blood pressure values
Description
Analysis performed for the ambulatory blood pressure monitoring (ABPM) - subgroup
Time Frame
Baseline, up to 12 weeks after start of treatment
Title
Number of patients with adverse events
Time Frame
Up to 16 weeks
Title
Number of patients with clinically significant changes in laboratory values
Time Frame
Up to 16 weeks
Title
Number of patients with clinically significant changes in ECG
Time Frame
Up to 16 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients with blood pressure levels of 140/90 mm Hg or higher (confirmed on 2 consecutive visits), who were 18 years old and older, regardless of sex
Exclusion Criteria:
Suspected or known diagnosis of arterial hypertension with a secondary cause
Women who were not using an effective method of contraception, or who were pregnant, or breast-feeding
Systolic blood pressure > 200 mm Hg or diastolic blood pressure > 115 mm Hg
Laboratory test values two fold above the upper normal limit
Previous intolerance to angiotensin conversion enzyme inhibitors or angiotensin II blocker (AIIAR)
New York Heart Association class III or IV heart failure
History of stroke in the 6 months prior to entry into the study
Uncontrolled type 2 diabetes mellitus, defined as fasting glucose levels > 140 mg/dL on 3 consecutive assessments
Patients who were included in another investigational drug study in the past 30 days
12. IPD Sharing Statement
Links:
URL
http://trials.boehringer-ingelheim.com
Description
Related Info
Learn more about this trial
Telmisartan in Mild to Moderate Hypertensive Patients
We'll reach out to this number within 24 hrs